Welcome to our dedicated page for MDNA news (Ticker: MDNA), a resource for investors and traders seeking the latest updates and insights on MDNA stock.
Medicenna Therapeutics (MDNA) provides this comprehensive news hub for stakeholders following advancements in targeted immunotherapies. Access verified updates on clinical-stage developments, research breakthroughs, and strategic partnerships driving innovation in cancer treatment.
Our curated news collection delivers essential information about MDNA's pipeline progress, including updates on IL-2/IL-4/IL-13 superkines, Empowered Cytokines research, and the T-MASK platform development. Investors and researchers will find timely reports on clinical trial milestones, regulatory developments, and collaborative research initiatives.
Key content categories include treatment efficacy data, intellectual property updates, and management commentary on therapeutic applications. All materials maintain rigorous standards for medical and financial accuracy, ensuring reliable decision-making support.
Bookmark this page for direct access to Medicenna's official communications and third-party analyses. Check regularly for updates on novel cytokine engineering approaches and their potential to transform oncology care paradigms.
Medicenna Therapeutics Corp. (NASDAQ: MDNA, TSX: MDNA) announced a conference call and live webcast scheduled for February 7, 2023, at 8:30 AM ET to discuss its third quarter fiscal 2023 financial results and operational highlights. The call can be accessed via telephone or through an online webcast. Medicenna focuses on developing innovative immunotherapies, including its IL-2 Superkine, MDNA11, which shows promise in stimulating cancer-fighting T cells. The company’s IL-4 Empowered Superkine, MDNA55, has undergone five clinical trials and holds Fast-Track and Orphan Drug designations from the FDA.
Medicenna Therapeutics Corp. has received U.S. Patent No. 11,542,312, granting IP protection for cancer treatment methods involving IL-2 Superkine and PD1/PDL1 or CTLA-4 checkpoint inhibitors. This patent extends through at least 2039 and is crucial for the ongoing ABILITY clinical trial using MDNA11. The company anticipates improved outcomes for patients unresponsive to traditional checkpoint inhibitors, potentially creating substantial market value as these patents expire after 2028. The patent complements Medicenna's portfolio, enhancing prospects for collaborations and partnerships.
Medicenna Therapeutics presented new data for MDNA11, a long-acting IL-2 super-agonist, at the SITC 37th Annual Meeting. The Phase 1/2 ABILITY study showed promising safety and pharmacodynamic profiles in advanced solid tumor patients. Key findings include tumor control in 5 of 14 patients, with a notable partial response in a metastatic pancreatic cancer patient. The study reports 92% of adverse events were Grade 1-2, with no dose-limiting toxicities. The ongoing trial's dose escalation phase will conclude with initial results expected in Q1 2023.
Medicenna Therapeutics Corp. (NASDAQ: MDNA) reported its Q3 fiscal 2022 financial results, highlighting a net loss of $0.9 million compared to $8.2 million in the same period last year. The company holds $40 million in cash and equivalents, funding operations through Q2 2024. The ABILITY study's low and mid-dose cohorts showed tumor control in 5 of 14 evaluated patients, including one confirmed partial response in pancreatic cancer. The partnership with Merck to evaluate MDNA11 in combination with KEYTRUDA® is also significant for further clinical development.
Medicenna Therapeutics Corp. (NASDAQ: MDNA) received a notice from Nasdaq on October 25, 2022, indicating non-compliance with the minimum bid price requirement of $1.00 per share. The notice does not affect trading or company operations immediately. Medicenna has until April 24, 2023, to regain compliance, which can be achieved if the stock closes above $1.00 for 10 consecutive business days. If non-compliance persists, the company may face potential delisting, although this notice does not impact its TSX listing.
Medicenna Therapeutics Corp. (NASDAQ: MDNA) announced a conference call on November 4, 2022, at 8:30 AM ET to discuss its second quarter fiscal 2023 financial results and operational highlights. The live webcast will be accessible through their website. Medicenna specializes in immunotherapy, focusing on advanced IL-2, IL-4, and IL-13 Superkines with MDNA11 showing promise in preferentially stimulating cancer-fighting T cells and NK cells. The IL-4 Empowered Superkine, MDNA55, has received Fast-Track and Orphan Drug status from the FDA.
Medicenna Therapeutics Corp. (NASDAQ: MDNA) announced the acceptance of two abstracts for poster presentations at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, scheduled from November 8 – 12, 2022, in Boston, MA.
The abstracts will be published on November 7, 2022, and detail studies on MDNA11, a long-acting IL-2 agonist. The first presentation covers pharmacokinetics and pharmacodynamics, while the second focuses on interim safety and anti-tumor activity.
Medicenna Therapeutics Corp. (NASDAQ: MDNA TSX: MDNA) has received conditional approval from the Toronto Stock Exchange to extend the expiry date of 1,549,052 common share purchase Warrants by nine months to July 17, 2023. The original expiry date was October 17, 2022, and the exercise price of $1.75 per share remains unchanged. A total of 1,661,552 Warrants are available for exercise, with 112,500 held by insiders not being extended. Medicenna focuses on developing advanced immunotherapy treatments, including IL-2 Superkines and Empowered Superkines.
Medicenna announced promising results from the Phase 1/2 ABILITY study of MDNA11, a long-acting IL-2 super-agonist. Notably, a fourth-line metastatic pancreatic cancer patient achieved a confirmed partial response after failing prior therapies. The tumor control rate was 36% among 14 evaluable patients, with signs of sustained anti-cancer activity observed. No dose-limiting toxicities have been reported as the trial progresses to a fifth dose-escalation cohort. The study aims to evaluate MDNA11's safety, pharmacokinetics, and anti-tumor efficacy both as a monotherapy and in combination with KEYTRUDA.
Medicenna Therapeutics (NASDAQ: MDNA) presented promising preclinical data on its anti-PD1-IL-2 BiSKIT™ and long-acting IL-4/IL-13 super-antagonist at the Cytokines 2022 conference. The BiSKIT™ exhibited superior efficacy in murine models of colon, skin, and breast cancer compared to conventional therapies. The IL-4/IL-13 super-antagonist showed monotherapy potential and synergy with IL-2 Superkine in targeting immunologically cold tumors. These findings highlight the innovative capabilities of Medicenna's Superkine platform and could lead to further collaborations in cancer immunotherapy.
